{"id":"W2611645469","doi":"10.1016/s2352-3026(17)30078-9","title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"European Commission; F. Hoffmann-La Roche","keywords":"Medicine; Rituximab; Follicular lymphoma; Vincristine; Internal medicine; Prednisone; International Prognostic Index; Clinical endpoint; Surgery; Cyclophosphamide; Lymphoma; Oncology; Chemotherapy; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003033042,0.0003102515,0.002852177,0.00005362714,0.0003667776,0.00003895598,0.0004163101,0.0001541708,0.00002870158],"category_scores_gemma":[0.0004015086,0.0001911568,0.000175273,0.00004663638,0.0004694243,0.00005433296,0.0001426173,0.00003947272,0.000007611628],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001564808,"about_ca_system_score_gemma":0.0002179682,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003901233,"about_ca_topic_score_gemma":0.0001561751,"domain_scores_codex":[0.9982826,0.000104715,0.0006384521,0.0003977159,0.0001611939,0.0004153313],"domain_scores_gemma":[0.996672,0.001267988,0.000607769,0.001224068,0.0001114978,0.0001166939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9021352,0.02385873,0.0001767736,0.0002777344,0.001405656,0.001102088,0.0005365448,0.000001501648,0.0001014882,0.003532675,0.0001783687,0.06669322],"study_design_scores_gemma":[0.9601752,0.02464908,0.0003151508,0.0001456919,0.001876779,0.001706966,0.00003092737,0.0001811149,0.005106784,0.0003381937,0.005313031,0.0001611436],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858407,0.0027343,0.00007051475,0.00432841,0.0003787192,0.005907883,0.0001973993,0.00002388782,0.0005181235],"genre_scores_gemma":[0.9953434,0.00277948,0.0008024849,0.00006072934,0.0002296851,0.0006169652,0.00006754973,0.00002973277,0.00006990601],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06653208,"threshold_uncertainty_score":0.7795146,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09747788966554995,"score_gpt":0.3848782168562778,"score_spread":0.2874003271907279,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}